The opening ceremony of the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute.
The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute", established by the special zone government and fully owned, officially opened today (21st) at the Hong Kong Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. The "Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Center" in Shenzhen Park also opened on the same day. The "one institute and one center" has become the first benchmark for the coordinated development of the "one zone and two parks" in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone. Secretary for Administration and Home Affairs, Cheuk Wing-hing, stated that the National "14th Five-Year Plan" clearly supports Hong Kong in building an international innovation and technology center. The "Development Plan for Shenzhen Park in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone" also strongly supports the coordinated development of science and te
The net inflow of Meituan in the Hong Kong Stock Connect is 0.484 billion Hong Kong dollars.
There was a net inflow of funds from Beishui Nanshang into Meituan (03690.HK), Tencent (00700.HK), and Alibaba (09988.HK), reaching 0.484 billion Hong Kong dollars, 0.274 billion Hong Kong dollars, and 85.3 million Hong Kong dollars respectively. There was a net outflow of funds from Beishui Nanshang to CNOOC (00883.HK) and Mobvista (01860.HK), reaching 0.18 billion Hong Kong dollars and 24.85 million Hong Kong dollars respectively. The highest net capital inflow of the Hong Kong Stock Connect (Shanghai) was in Tencent (00700.HK) with 0.303 billion Hong Kong dollars, while the highest net capital outflow was in Xiaomi Group (01810.HK) with 87.3 million.
Northbound capital direction | Northbound trading net buy of 5.571 billion, local capital increased its position in Innovent Bio (01801) by nearly 0.3 billion, and all day selling of CM Bank (03968).
On November 20, in the Hong Kong stock market, northbound capital recorded a net buy of 5.571 billion HKD, of which the Shanghai-Hong Kong Stock Connect had a net buy of 3.013 billion HKD, and the Shenzhen-Hong Kong Stock Connect had a net buy of 2.559 billion HKD.
The Hang Seng Index rose by 41 points, Kingsoft surged quickly, while Xpeng retraced after its results.
nvidia (NVDA.US) rose nearly 5% before the earnings announcement, leading the Nasdaq to gain 195 points or 1% on the night of the 19th, while the Dow dropped 120 points or 0.3%. Hong Kong stocks fluctuated upward. The Hang Seng Index opened 40 points lower, initially dropped 87 points to 19,575 points, then rebounded, at one point rising 89 points to 19,752 points, ultimately closing up 41 points or 0.2% at 19,705 points; the national index rose 6 points or 0.1% to close at 7,090 points; the hang seng tech index rose 18 points or 0.4% to close at 4,413 points. The total trading volume of the market for the day was 114.671 billion yuan. Alibaba-W (09988.HK)
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Major bank rating | UBS Group: Raised Innovent Bio target price to 61.4 Hong Kong dollars, expecting the first dual-target GLP-1 drug for weight loss to be approved for use in the first half of next year.
Gelonghui November 20th | UBS report indicates that before the recent launch of the new type of blood sugar-lowering drug GLP-1, only 0.1% of overweight or obese individuals in the mainland received clinical treatment due to the lack of convenient, affordable, and effective treatment. The clinical trial results and positive feedback of GLP-1 are expected to significantly penetrate the weight loss market and the type 2 diabetes market, with the drug already holding a 14% market share in the latter. The report predicts that in 2034, Innovent Bio's Marzydutide is expected to achieve an 18% market share in the Chinese GLP-1 market, based on the drug's three advantages, including being expected to be the first dual-target drug in the first half of next year.